Newsletter

We are delighted to announce the renewal of ETAP-Lab's ISO 9001 certification. This achievement underlines our commitment to providing exemplary preclinical research services.   A commitment to quality and customer satisfaction   Our robust quality management system, backed by our ISO9001 certification, ensures to our customers: compliance with rigorous quality standards: we follow established protocols and guidelines to ensure the accuracy and reliability of our services. Continuous improvement: We constantly focus on improving our processes and services, driven by a commitment to excellence. Customer-focused

🌍ETAP-Lab is happy to present a poster at the 16th World Stroke Congress (WSC 2024) in Abu Dhabi, UAE, from October 23-26, 2024 organized by the World Stroke Organization.   ETAP-Lab's team is looking forward to attending this global event that explores "the forefront of stroke and cerebrovascular disease topics and present the most influential late breaking clinical trials". As a preclinical efficacy CRO, ETAP-Lab will unveil its poster on original preclinical results about in vivo assays on Stroke disease. The results presented

Better than any certification, at ETAP-Lab we believe that customer recognition is the ultimate goal. We're proud to announce our strategic partnership with Kisolite Corp, a leader in innovative therapeutic solutions. Together, we're advancing in vivo studies for their treatment targeting Inflammatory Bowel Disease (IBD). Our dedication to building lasting relationships goes beyond expertise. Our flexible and human-sized organization offers personalized support, ensuring clients feel empowered throughout the research process.   Ready to collaborate on your next drug efficacy study? Contact us today

📌ETAP-Lab's team will attend the upcoming NEUROSCIENCE 2024 from Saturday, October 5 to Wednesday, October 9, in Chicago (IL, USA), in McCormick Place Convention Center. That meeting is the World's Largest Neuroscience Conference, organized by the Society For Neuroscience (SFN), and with an exciting programming for the scientists coming from around the world!   ETAP-Lab will unveil two posters on original preclinical results about in vitro and in vivo assays on Alzheimer's disease.   📅Let's meet our scientists during the poster sessions   Nicolas Violle, CEO

ETAP-Lab will attend the upcoming NLSDays on next September 18 - 19, 2024, in Malmö, Sweden for partnering opportunities. We are delighted to participate for the first time to Nordic Life Science Days, the largest Nordic partnering conference dedicated to the life science industry.   🎯 Explore our wide range of services, from gold-standard to tailored models designed to tackle your challenges You look forward accelerating & derisking the development of your drugs and/or medical devices in Dermatology, Neurology, or Cardiology thanks to preclinical

ETAP-Lab will showcase its expertise at the 53rd ANNUAL ESDR MEETING on next September 4-7, 2024, in Lisbon (Portugal), organized by the European Society for Dermatological Research.   🎯 Discover our gold standard models and our tailored solutions to meet your specific challenges! At ETAP-Lab, French preclinical CRO for over 30 years, we offer in vivo preclinical research services in Dermatology field. Leveraging our gold standard models and tailor-made solutions, we address your challenges in molecule development, spanning across areas such as psoriasis, atopic

To support our growth and our preclinical research activities, we're investing in new facilities! We are glad to unveil the new plans for ETAP-Lab's future building in Nancy-Chavigny, in the Brabois forestière business park! 🔬To support our research activity in the fields of dermatology and neurology, our new premises will incorporate larger laboratories, more office space for the support departments and all the facilities to ensure the well-being of our employees, all in a building with a footprint of 1600m², including 700m²

The ETAP-Lab group, specialized in the preclinical evaluation of the efficacy of innovative therapies for the pharmaceutical industry, is recruiting several people specialized in preclinical in vivo cardiology for its Marseille site SYNCROSOME! Do you want to join a fast-growing, flexible and human-sized organization that designs and carries out customized experimental protocols? Beyond science, we pay particular attention to ethics, animal welfare, sustainable development and the validation of the most recent techniques.   The offers in a few words

Syncrosome is proud to attend the next Heart Failure Drug Discovery & Development Summit as an event partner, which will take place from 31 July to 1 August 2024, in Boston (USA, MA)! We look forward to participating in the 3rd HF Drug Discovery & Development Summit, which returns to tackle the major challenges facing preclinical heart failure drug development by bringing together more than 50 biopharmas delve into targeting, stratifying and treating cardiomyopathies with greater precision. A fine programme of scientific